Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
- Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
May 29, 2024
- Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
May 29, 2024
- Novel Antibiotic Fetroja Now Available in Taiwan: Shionogi
May 29, 2024
- Cheplapharm to Take Over 2 More Brands from Clinigen in Japan
May 29, 2024
- Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
- Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
- Daiichi Sankyo’s TROP2 ADC Shows OS Benefit in Subgroup of NSCLC
May 28, 2024
- Alzheimer’s Med Leqembi Approved in South Korea, Its 4th Market
May 28, 2024
- Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
- MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
- AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
- Santen Recalls All Lots of Diquas LX, Halts Supply for Preservative Issue
May 23, 2024
- Daiichi Sankyo Sets Up New Research Sites in US, Germany
May 23, 2024
- Otsuka Axes Alzheimer’s Agitation Drug, Cuts Half-Year Profit Outlook
May 23, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…